Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 12/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA3 | P07451 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.32 |
| ▸ | F11 | P03951 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21018964 | 0.86 | LPL (0.33) | LPLLIPG | |
| SCHEMBL332693 | 0.76 | LPL (0.36) | LPLLIPGFFAR1CA1CA2 | |
| SCHEMBL22049117 | 0.75 | IRAK4 (0.30) | — | |
| SCHEMBL24141578 | 0.74 | LPL (0.38) | LPLLIPGFFAR1CA1CA2 | |
| SCHEMBL20919403 | 0.71 | LPL (0.33) | LPLLIPGFFAR1P2RX7 | |
| SCHEMBL19207350 | 0.71 | FFAR1 (0.39) | LPLLIPGFFAR1P2RX7 | |
| SCHEMBL1530333 | 0.71 | LPL (0.39) | LPLLIPGFFAR1F11P2RX7 | |
| SCHEMBL1485368 | 0.71 | ALDH1A1 (0.35) | LPLLIPGFFAR1P2RX7 | |
| SCHEMBL21023551 | 0.70 | FFAR1 (0.35) | LPLLIPGFFAR1 | |
| SCHEMBL24373133 | 0.70 | LPL (0.35) | LPLLIPGFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030866-B2 | 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD | SPRINGWORKS THERAPEUTICS, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| WO-2023122780-A9 | 2-PYRAZOLE ANILINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | THE KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
| US-20230295166-A1 | ATR INHIBITORS AND USES THEREOF | ANTENGENE DISCOVERY LIMITED (CN) | 2023-09-21 | — | — | US | disclosed |
| US-20230278982-A1 | 2-Pyrazole Anilines and Related Analogs for Inhibiting YAP/TAZ-TEAD | KU LEUVEN R&D (BE) | 2023-09-07 | — | — | US | disclosed |
| US-20230234958-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | D. E. SHAW RESEARCH, LLC | 2023-07-27 | — | — | US | disclosed |
| US-20230192734-A1 | TRICYCLIC COMPOUNDS AS EGFR INHIBITORS | QILU PHARMACEUTICAL CO LTD (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20220340576-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
| US-20220315586-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | SCHRODINGER, INC. | 2022-10-06 | — | — | US | disclosed |
| US-20220213103-A1 | 9H-PYRROLO-DIPYRIDINE DERIVATIVES | UCB Biopharma SRL (BE) | 2022-07-07 | — | — | US | disclosed |
| US-11312716-B2 | 9H-pyrrolo-dipyridine derivatives | UCB Biopharma SRL | 2022-04-26 | — | — | US | disclosed |
| US-10934302-B1 | SHP2 phosphatase inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-20210047326-A1 | 9H-PYRROLO-DIPYRIDINE DERIVATIVES | UCB BIOPHARMA SRL (SOCIETE A RESPONSABILITE LIMITEE) (BE) | 2021-02-18 | — | — | US | disclosed |
| US-20180022748-A1 | 9H-PYRROLO-DIPYRIDINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213103-A1 | 9H-PYRROLO-DIPYRIDINE DERIVATIVES | MAPT, PSEN1, PRNP | LPL 4101/4885LIPG 4343/4885FFAR1 4243/4885 |
| US-20220340576-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPRCAP, PTPN22, PTPN1 | LPL 742/4885LIPG 375/4885FFAR1 2629/4885 |
| US-20230234958-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPRCAP, PTPN22, PTPN1 | LPL 742/4885LIPG 375/4885FFAR1 2629/4885 |
| US-20210047326-A1 | 9H-PYRROLO-DIPYRIDINE DERIVATIVES | MAPT, PSEN1, PRNP | LPL 4101/4885LIPG 4343/4885FFAR1 4243/4885 |
| US-20230192734-A1 | TRICYCLIC COMPOUNDS AS EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | LPL 4291/4885LIPG 1888/4885FFAR1 2900/4885 |
| US-20230295166-A1 | ATR INHIBITORS AND USES THEREOF | ATR, CHEK1, CHEK2 | LPL 3676/4885LIPG 2639/4885FFAR1 4571/4885 |
| US-20230278982-A1 | 2-Pyrazole Anilines and Related Analogs for Inhibiting YAP/TAZ-TEAD | YAP1, TEAD3, TEAD2 | LPL 3336/4885LIPG 2634/4885FFAR1 4187/4885 |
| US-11312716-B2 | 9H-pyrrolo-dipyridine derivatives | MAPT, PSEN1, PRNP | LPL 4101/4885LIPG 4343/4885FFAR1 4243/4885 |
| US-20180022748-A1 | 9H-PYRROLO-DIPYRIDINE DERIVATIVES | MAPT, PSEN1, PRNP | LPL 4101/4885LIPG 4343/4885FFAR1 4243/4885 |
| US-10934302-B1 | SHP2 phosphatase inhibitors and methods of use thereof | PTPRCAP, PTPRJ, PTPRC | LPL 611/4885LIPG 339/4885FFAR1 3459/4885 |
| US-12030866-B2 | 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD | YAP1, TEAD3, TEAD2 | LPL 3336/4885LIPG 2634/4885FFAR1 4187/4885 |
| US-20220315586-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPRCAP, PTPN22, PTPN1 | LPL 742/4885LIPG 375/4885FFAR1 2629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.